BUZZ-Regeneron rises on new dividend program, Q4 results beat

Shares of drugmaker Regeneron Pharmaceuticals REGN.O rise ~2% to $680.40 premarket

REGN says its board approved a cash dividend program, paying 88 cents per share to shareholders on March 20

Co announces an additional $3 bln share repurchase program, bringing total current capacity to around $4.5 bln

Brokerage Evercore ISI says "dividend should help attract new investors to the name" without altering REGN's capital allocation priorities

Co also reports Q4 adj. profit of $12.07 per share, above analysts' est. of $11.28, according to LSEG data, driven by strong demand for its eczema drug, Dupixent

Co posts Q4 sales of $3.79 bln vs. analysts' expectations of $3.75 bln - LSEG

Dupixent sales came in at $3.70 bln, compared to $3.22 bln a year ago

REGN fell 21.3% in 2024